Clinical Trial Results: Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating fractionated gemtuzumab ozogamicin followed by non-engraftment donor leukocyte infusions for relapsed/refractory acute myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gemtuzumab ozogamicin (fractionated regimen) (gemtuzumab ozogamicin)
• Non-engraftment donor leukocyte infusions

Snippet

Sponsor: Brown University | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-07-23